Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.56
+0.11 (1.16%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $20.9. The average 1-year stock price forecast is 118.62% higher than the current stock price, while the lowest is $19.75 (+106.59%) and the highest is $22.53 (+135.67%).
Price Target: $20.9 (+118.62%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
910.22M
from 803.79M
Increased by 13.24%
Revenue Next Year
1.07B
from 910.22M
Increased by 17.13%
EPS This Year
0.01
from -0.02
EPS Next Year
0.08
from 0.01
Increased by 1,026.90%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 933.7M | ||
| Avg | 910.2M | ||
| Low | 889.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.2% | ||
| Avg | 13.2% | ||
| Low | 10.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.07 | ||
| Avg | 0.01 | ||
| Low | -0.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |